Adela’s tissue-agnostic MRD test has been clinically validated to predict and surveil for recurrence in patients with head & ...

Natera has released new data from the GALAXY arm of its ongoing CIRCULATE-Japan trial showing the efficacy of its molecular ...

Drs Kathy D. Miller and Heather A. Parsons explore the complexities and evolving strategies in managing HER2+ oligometastatic ...

Certain genetic changes, or mutations, can increase the chances of leukemia or blood cancer. According to experts, leukemia, ...

MRD testing can better stratify patients by risk of recurrence compared to the current standard of care because ctDNA provides higher-resolution detection of persistent disease in the post ...

Reid W. Merryman, MD, discussed the latest developments with minimal residual disease assays in the management of patients ...

This data provides the first evidence of Signatera-based molecular residual disease (MRD) detection to predict overall survival (OS) and highlights Signatera’s ability to predict adjuvant chemotherapy ...

Personalis, Inc. (Nasdaq: PSNL), a leader in MRD testing, announced findings presented this week at the European Society of Medical Oncology Congress (ESMO) Congress 2024 in Barcelona, Spain.

Reid Merryman, MD, discusses the role of minimal residual disease in lymphoma and his presentation on the topic at the 2024 ...

Researchers developed RAPTOR, a patent-pending optical counterfeit detection method for chips used in semiconductor devices. It leverages deep learning to identify tampering. It improves upon ...

Findings presented at the 2024 SOHO Annual Meeting showed that among patients in the D-VRd arm (n = 355), 57.5% were MRD negative at a 10-5 sensitivity at the end of consolidation vs 32.5% of ...

The resDetect ™ tool addresses these resDNA quality control challenges via a comprehensive range of highly sensitive residual host cell nucleic acid detection kits across numerous host cell types.